These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10363584)

  • 21. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
    Fujita K; Yamamoto W; Endo S; Endo H; Nagashima F; Ichikawa W; Tanaka R; Miya T; Araki K; Kodama K; Sunakawa Y; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Kamataki T; Sasaki Y
    Cancer Sci; 2008 May; 99(5):1049-54. PubMed ID: 18380793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunotoxic effects of a new antineoplastic agent S-1 in mice--comparison with S-1, UFT and 5-FU].
    Kouchi Y; Maeda Y; Morinaga H; Ohuchida A
    J Toxicol Sci; 1996 Nov; 21 Suppl 3():691-701. PubMed ID: 9021669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
    Yoshisue K; Masuda H; Matsushima E; Ikeda K; Nagayama S; Kawaguchi Y
    Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
    Usuki H; Ishimura K; Yachida S; Hagiike M; Okano K; Izuishi K; Karasawa Y; Goda F; Maeta H
    Gastric Cancer; 2003; 6 Suppl 1():66-70. PubMed ID: 12775023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats].
    Ogata Y; Akagi Y; Nozoe Y; Sasatomi T; Miyagi Y; Nakagawa M; Matono K; Kobayashi H; Shirouzu K
    Gan To Kagaku Ryoho; 2001 May; 28(5):655-60. PubMed ID: 11383214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
    Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil.
    Fukushima M; Shimamoto Y; Kato T; Uchida J; Yonekura R; Ohshimo H; Shirasaka T
    Anticancer Drugs; 1998 Oct; 9(9):817-23. PubMed ID: 9840729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacokinetics of S-1].
    Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral administration of uracil-tegafur (UFT) inhibits liver micrometastasis of human colon cancer in an orthotopic nude mouse model and its early detection system.
    Takahashi Y; Yamashita K; Endo Y; Sasaki T; Mai M
    Surg Today; 2004; 34(10):855-9. PubMed ID: 15449156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. S-1 in gastric cancer: a comprehensive review.
    Maehara Y
    Gastric Cancer; 2003; 6 Suppl 1():2-8. PubMed ID: 12775012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.
    Kato T; Shimamoto Y; Uchida J; Ohshimo H; Abe M; Shirasaka T; Fukushima M
    Anticancer Res; 2001; 21(3B):1705-12. PubMed ID: 11497250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan.
    Shirasaka T; Yamamitsu S; Tsuji A; Taguchi T
    Invest New Drugs; 2000 Nov; 18(4):315-29. PubMed ID: 11081568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors.
    van Groeningen CJ; Peters GJ; Schornagel JH; Gall H; Noordhuis P; de Vries MJ; Turner SL; Swart MS; Pinedo HM; Hanauske AR; Giaccone G
    J Clin Oncol; 2000 Jul; 18(14):2772-9. PubMed ID: 10894878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant tegafur-uracil (UFT) or S-1 monotherapy for advanced gastric cancer: a single center experience.
    Yen HH; Chen CN; Yeh CC; Lai IR
    World J Surg Oncol; 2021 Apr; 19(1):124. PubMed ID: 33865416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased intestinal permeability correlates with gastrointestinal toxicity among formulations of the fluorouracil analogue tegafur in rats.
    Korenaga D; Honda M; Yasuda M; Inutsuka S; Nozoe T; Tashiro H
    Eur Surg Res; 2002; 34(5):351-6. PubMed ID: 12364819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.
    Hoff PM
    Invest New Drugs; 2000 Nov; 18(4):331-42. PubMed ID: 11081569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Other fluorinated pyrimidines in the treatment of solid tumors.
    Saad ED; Hoff PM
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):65-8. PubMed ID: 11219980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The feasibility of oral fluoropyrimidines as adjuvant chemotherapy after resection and local coagulation therapy of colorectal liver metastases].
    Narita T; Seshimo A; Itabashi M; Aratake K; Ogawa S; Hirosawa T; Hashimoto T; Amano K; Kameoka S
    Gan To Kagaku Ryoho; 2011 Nov; 38(11):1821-4. PubMed ID: 22083190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant effects of calmodulin antagonists on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur) and a mixture of ftorafur and uracil (UFT) in nude mice bearing human ovarian carcinomas.
    Kikuchi Y; Oomori K; Iwano I; Kizawa I; Miyauchi M; Kita T; Kuki E
    Gynecol Oncol; 1989 Nov; 35(2):172-6. PubMed ID: 2509301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.